



**FOR IMMEDIATE RELEASE**  
**November 2, 2007**

**IMRIS INC. COMPLETES \$40 MILLION  
INITIAL PUBLIC OFFERING**

**WINNIPEG, Manitoba, November 2, 2007-** IMRIS Inc. ("IMRIS") or (the "Company") announced today that it has successfully completed its initial public offering (the "Offering") of 6,666,667 common shares at a price of C\$6.00 per share for gross proceeds of C\$40 million. The Company's common shares begin trading today on the Toronto Stock Exchange under the symbol "IM".

The oversubscribed Offering was sold through an underwriting syndicate led by RBC Capital Markets and included BMO Capital Markets, TD Securities Inc., Canaccord Capital Corporation and GMP Securities L.P. The Company has granted the underwriting syndicate an over-allotment option to purchase up to an additional 1,000,000 common shares at the price of C\$6.00 per share. The option is exercisable, in whole or in part, within the next 30 days to cover any over-allotments and for market stabilization purposes. If the option is exercised in full, gross proceeds of the Offering will be approximately C\$46 million.

David Graves, President and Chief Executive Officer commented, "The successful completion of our IPO makes an important statement of investor confidence in IMRIS' breakthrough surgical imaging technology. The capital raised by this offering will provide the resources to address two exciting opportunities, the expansion of our sales and marketing plan for the IMRISneuro surgical suite and the continued development of our IMRIScardio surgical suite, serving to drive our growth as we expand our addressable markets."

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

**About IMRIS**

IMRIS is a global leader in surgical imaging solutions designed to improve patient outcomes and help them live longer and more enjoyable lives. IMRIS' key technology benefits of high resolution MR images, improved patient safety, enhanced surgical efficiency and increased financial viability for hospitals contribute to a breakthrough surgical imaging offering.

The Company's lead product, IMRISneuro, has been validated by leading U.S. neurosurgeons and is increasingly being used by world-class neuroscience centres. IMRIS core MRI technology has multiple product applications with a second product suite, IMRIScardio, which is actively under development.

For more information, see [www.imris.com](http://www.imris.com)

### **Forward-Looking Statements**

This press release may contain or refer to forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that actual results will be consistent with such statements. Forward-looking statements are subject to significant risks and uncertainties, and other factors that could cause actual results to differ materially from expected results. These forward-looking statements are made as of the date hereof and we assume no responsibility to update or revise them to reflect new events or circumstances.

-- 30 --

### **For further information:**

**Ron Sabourin**  
**Executive Vice President Finance**  
**and Chief Financial Officer**  
**IMRIS Inc.**  
**Tel: (204) 480-7090**  
**Email: [rsabourin@imris.com](mailto:rsabourin@imris.com)**

**Susan McLeod**  
**Manager, Marketing**  
**Communications**  
**IMRIS Inc.**  
**Tel: (204) 480-7094**  
**Email: [smcleod@imris.com](mailto:smcleod@imris.com)**